Loading...
Please wait, while we are loading the content...
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy
| Content Provider | Scilit |
|---|---|
| Author | Goltz, Diane Gevensleben, Heidrun Dietrich, Jörn Ellinger, Jörg Landsberg, Jennifer Kristiansen, Glen Dietrich, Dimo |
| Copyright Year | 2016 |
| Description | Biomarkers that facilitate the prediction of disease recurrence in prostate cancer (PCa) may enable physicians to personalize treatment for individual patients. In the current study, PD-1 (PDCD1) promoter methylation was assessed in a cohort of 498 PCa patients included in The Cancer Genome Atlas (TCGA) and a second cohort of 300 PCa cases treated at the University Hospital of Bonn. In the TCGA cohort, the PD-1 promoter was significantly hypermethylated in carcinomas versus normal prostatic epithelium (55.5% vs. 38.2%, p < 0.001) and PD-1 methylation (mPD-1) inversely correlated with PD-1 mRNA expression in PCa (Spearman's ρ = −0.415, p < 0.001). In both cohorts, mPD-1 significantly correlated with preoperative prostate specific antigen (PSA). In univariate Cox Proportional Hazard analysis, mPD-1 served as a significant prognostic factor for biochemical recurrence (BCR)-free survival (Hazard ratio: HR = 2.35 [1.35–4.10], p = 0.003, n = 410) in the TCGA cohort. In multivariate analysis, mPD-1 was shown to add significant independent prognostic information adjunct to pathologic tumor category (pT) and Gleason grading group (HR = 2.08 [1.16–3.74], p = 0.014, n = 350). PD-1 promoter methylation analyses could thus potentially aid the identification of patients which might benefit from adjuvant treatment after radical prostatectomy. Moreover, our data suggest an intrinsic role of PD-1 in PCa carcinogenesis and disease progression, which needs to be addressed in future studies. |
| Related Links | https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1221555?needAccess=true https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087295/pdf |
| e-ISSN | 2162402X |
| DOI | 10.1080/2162402x.2016.1221555 |
| Journal | OncoImmunology |
| Issue Number | 10 |
| Volume Number | 5 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2016-09-02 |
| Access Restriction | Open |
| Subject Keyword | Journal: Oncoimmunology Andrology Dna Methylation Pd-1 Pdcd1 Prognostic Biomarker Prostate Cancer |
| Content Type | Text |
| Resource Type | Article |
